Published Date: 08/14/2023
Expiration Date: 07/11/2026
Anti-HIV broadly neutralizing antibodies (bNAbs), alone or in combination, are some of the most exciting agents in the pipeline for the prevention, management, salvage, and potential cure of HIV. Dr. Marina Caskey, one of the most prominent researchers leading the way in this new field of immunotherapy, returns with an update on bNAbs in clinical development, and results from HIV-prevention trials utilizing bNAbs.
Marina Caskey, MD is a Professor of Clinical Investigation at The Rockefeller University. Her work focuses on the development and clinical evaluation of novel immunotherapeutic strategies against infectious diseases, with a special emphasis on HIV. Dr. Caskey has led a series of early-phase clinical studies to evaluate the safety and efficacy of broadly neutralizing anti-HIV antibodies. These studies have revitalized this area of HIV research, which had been abandoned after first-generation antibodies failed to show significant effects in humans. Broadly neutralizing antibodies are now considered one of the most promising strategies to achieve HIV remission, as well as potential alternatives to antiretrovirals for both therapy and prevention. Dr. Caskey is also an attending physician in infectious diseases at Weill Cornell Medicine Center and an elected member of the American Society of Clinical Investigation.
